Anti-PD-1 antibody is named as an intervention in 9 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Chinese PLA General Hospital (5). The most-studied condition is Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
NCT07822646 · ClinicalTrials.gov ↗ · Ovarian Cancer
|
Phase 3 | Recruiting | Chinese PLA General Hospital | China |
|
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
NCT05769816 · ClinicalTrials.gov ↗ · Chronic Hepatitis b, Anti-PD-1 Antibody
|
Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | China |
|
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
NCT05771402 · ClinicalTrials.gov ↗ · Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNฮฑ
|
Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | China |
|
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
NCT06393361 · ClinicalTrials.gov ↗ · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
|
Phase 2 | Recruiting | Chinese PLA General Hospital | China |
|
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
NCT07602049 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma (STS), Osteosarcoma
|
Phase 2 | Recruiting | Sun Yat-sen University | China |
|
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
NCT05631886 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Lymphoma, EphA2 Overexpression
|
Phase 1 | Recruiting | Chinese PLA General Hospital | China |
|
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
NCT06563778 · ClinicalTrials.gov ↗ · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
|
Phase 2 | Not yet open | Chinese PLA General Hospital | China |
|
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
|
Phase 1/2 | Active, closed | CARsgen Therapeutics Co., Ltd. | China |
|
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V
|
Phase 1 | Active, closed | Chinese PLA General Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma | 2 |
| Solid Tumor, Adult | 2 |
| EphA2 Overexpression | 2 |
| Chronic Hepatitis b | 2 |
| Anti-PD-1 Antibody | 2 |
| Ovarian Cancer | 1 |
| Lymphoma | 1 |
| TP53 R273H | 1 |
| Soft Tissue Sarcoma (STS) | 1 |
| Osteosarcoma | 1 |
| Peg-IFNฮฑ | 1 |
| KRAS G12V | 1 |
| KRAS G12C | 1 |
| Gastric Adenocarcinoma | 1 |
| Pancreatic Cancer | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Chinese PLA General Hospital | 5 |
| The Second Affiliated Hospital of Chongqing Medical University | 2 |
| Sun Yat-sen University | 1 |
| CARsgen Therapeutics Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 6 |
A trial with sites in more than one country appears in each of those registers.
9 current trials in our China register name Anti-PD-1 antibody as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 9 trials are recruiting: 6 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Chinese PLA General Hospital (5), The Second Affiliated Hospital of Chongqing Medical University (2), Sun Yat-sen University (1) and CARsgen Therapeutics Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anti-PD-1 antibody works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Anti-PD-1 antibody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anti-PD-1 antibody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.